STERIS (NYSE:STE) Releases FY25 Earnings Guidance

STERIS (NYSE:STE) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $9.05-$9.25 for the period, compared to the consensus earnings per share estimate of $9.15.

STERIS Price Performance

Shares of STE stock traded up $1.37 during trading hours on Tuesday, hitting $239.27. The stock had a trading volume of 844,912 shares, compared to its average volume of 487,674. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.08 and a quick ratio of 2.36. The stock has a market capitalization of $23.65 billion, a price-to-earnings ratio of 63.19 and a beta of 0.83. STERIS has a one year low of $195.47 and a one year high of $243.19. The stock’s 50-day moving average price is $224.15 and its two-hundred day moving average price is $222.44.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, May 8th. The medical equipment provider reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.41 by $0.17. The business had revenue of $1.42 billion during the quarter, compared to analysts’ expectations of $1.41 billion. STERIS had a return on equity of 13.73% and a net margin of 6.95%. The firm’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.30 EPS. Equities analysts forecast that STERIS will post 9.16 EPS for the current year.

STERIS Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 20th. Investors of record on Thursday, September 5th will be issued a $0.57 dividend. This is an increase from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, September 5th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 0.95%. STERIS’s dividend payout ratio (DPR) is presently 59.69%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on STE shares. Piper Sandler restated a neutral rating and set a $225.00 price objective (up from $220.00) on shares of STERIS in a research report on Friday, May 10th. Needham & Company LLC reissued a hold rating on shares of STERIS in a research report on Friday, May 10th. JMP Securities restated a market outperform rating and issued a $265.00 price target on shares of STERIS in a research report on Friday, July 26th. Finally, StockNews.com lowered shares of STERIS from a buy rating to a hold rating in a research note on Monday. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of Hold and a consensus price target of $241.60.

Insider Buying and Selling

In other news, SVP Cary L. Majors sold 2,024 shares of the business’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $232.13, for a total transaction of $469,831.12. Following the completion of the sale, the senior vice president now directly owns 11,369 shares of the company’s stock, valued at $2,639,085.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, VP Renato Tamaro sold 1,154 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $231.64, for a total value of $267,312.56. Following the transaction, the vice president now owns 6,677 shares of the company’s stock, valued at $1,546,660.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Cary L. Majors sold 2,024 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $232.13, for a total value of $469,831.12. Following the transaction, the senior vice president now owns 11,369 shares in the company, valued at $2,639,085.97. The disclosure for this sale can be found here. In the last three months, insiders sold 7,762 shares of company stock valued at $1,798,477. Insiders own 1.14% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.